Keosys’ web-based imaging reading software has been designed specifically for clinical trials in order to limit reader subjectivity, increase measurement and quantification accuracy, and improve all-around operational efficiency, data quality, and traceability. The reading software includes advanced tools such as a lesion management system and dedicated applications for various response criteria in specific therapeutic areas. Our reading software is FDA 510 (k) cleared and ISO 13485 (Medical Devices) compliant.
Keosys’ high-performance and intuitive image-reading software is fully embedded inside our Imagys web platform. Results from lesion lists or reader measurements are automatically put into the reading forms (eCRF) to reduce the risk of human error. Our software also provides programmatic checks of rules and validation according to each criteria, thereby reducing reader subjectivity.
Keosys has invested in numerous imaging research programs, including granted projects that have led to advanced imaging algorithms and publications. Advanced imaging capabilities include MRI diffusion imaging (DWI/ADC), smart volumetric tumor analysis (L. Schwartz, Columbia University, NY), dynamic fused hybrid imaging (PET/CT/MRI), Total Metabolic Tumor Volume (TMTV) analysis, full support of nuclear medicine imaging, and SPECT dosimetry analysis software.
Our Read System was fully developed in-house in collaboration with practicing radiologists from all over the world. This web-based software relies on cutting edge technology that includes massive parallel and advanced Graphics Processing Unit (GPU) computing. GPU computing allows for faster processing times, which in turn allows each of our reviewers to access the software from anywhere. The result: faster turnaround times for our end customers.
Our reading software has been validated with all major vendors and supports many modalities including CT, MRI, PET, PET/CT, SPECT, SPECT/CT, conventional radiology, videos, photos, and more.
